United States

Alimera Sciences Inc (ALIM.O)

ALIM.O on Consolidated Issue listed on NASDAQ Global Market

28 Apr 2017
Change (% chg)

$0.02 (+1.27%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for ALIM.O


Alimera Sciences, Inc. (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina. The... (more)


Beta: 2.17
Market Cap(Mil.): $103.78
Shares Outstanding(Mil.): 64.86
Dividend: --
Yield (%): --


  ALIM.O Industry Sector
P/E (TTM): -- 29.08 30.08
EPS (TTM): -0.66 -- --
ROI: -72.39 13.73 13.25
ROE: -- 14.68 14.41

BRIEF-Alimera Sciences signs agreement for exclusive distributor of Iluvien in Spain

* Alimera Sciences signs agreement for exclusive distributor of Iluvien in Spain

Mar 13 2017

BRIEF-Alimera Sciences Q4 adjusted non-gaap loss per share $0.10

* Alimera sciences reports record fourth quarter and full year 2016 financial results

Mar 01 2017

BRIEF-Alimera Sciences and Knight Therapeutics file new drug submission for iluvien in Canada

* Alimera Sciences and Knight Therapeutics announce filing of new drug submission for iluvien in Canada

Feb 22 2017

BRIEF-Alimera Sciences says its unit Alimera Sciences Ltd received pricing, reimbursement decree for ILUVIEN on Jan. 11

* Alimera Sciences-unit Alimera Sciences received pricing and reimbursement decree for ILUVIEN from Agenzia Italiana Del Farmaco (AIFA) on Jan 11, 2017 Source text for Eikon: Further company coverage:

Feb 06 2017

BRIEF-Stonepine Capital LP reports 5.4 pct passive stake in Alimera Sciences

* Stonepine Capital LP reports 5.4 percent passive stake in Alimera Sciences Inc as of Nov 7 - sec filing Source text : http://bit.ly/2eKIZdy Further company coverage:

Nov 17 2016

BRIEF-Alimera Sciences reports Q3 loss per share $0.16

* Q3 earnings per share view $-0.11, revenue view $10.5 million -- Thomson Reuters I/B/E/S

Nov 02 2016

More From Around the Web


Earnings vs. Estimates